GH
GH Research PLC
GHRS · NASDAQ
$21.11 +3.23% (+$0.66)
1M -22.62%
Market Cap $1.40B
P/E Ratio -
Div. Yield -
ROE 20.86%
Bulios Fair Price
$11.15
47.2% downside
Current Price
$21.11
Undervalued Fair Value Overvalued
According to Bulios Fair Price, GHRS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
1/9Valuation
52 /100
Fair P/B 3.90x
P/E N/A
EV/EBITDA N/A
Growth
44 /100
Stable Book val. growth 3.84%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
FCF margin N/A
Quality
0 /100
Poor ROIC 19.85%
ROE 20.86%
Asset turnover 0.00x
Debt
69 /100
Low Debt/Equity 0.00x
Current ratio 28.70x
Int. coverage -308.80x
Stability
20 /100
Unstable Beta 1.28x
EPS volatility 218.20%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about GHRS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Velichka Valcheva
Employees
73
Headquarters
Dublin
Upcoming events
05 NOV
Earnings
Upcoming earnings report